trending Market Intelligence /marketintelligence/en/news-insights/trending/9xZ7lNEMRy-e2A165P7YDA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA accepts Sunovion's resubmitted application for Parkinson's therapy

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

US FDA accepts Sunovion's resubmitted application for Parkinson's therapy

Sunovion Pharmaceuticals Inc. said the U.S. Food and Drug Administration has accepted the resubmitted marketing application for its apomorphine film that is placed under the tongue to treat motor fluctuations in patients with Parkinson's disease.

The Marlborough, Mass.-based private pharmaceutical company in November resubmitted the new drug application for APL-130277, which treats the re-emergence or worsening of Parkinson's symptoms between medication dosages. About 40% to 60% of patients with Parkinson's disease experience these so-called off periods, resulting in tremors, stiffness or slow movement.

The U.S. regulator rejected an earlier application by Sunovion in January and issued a complete response letter requesting the company provide additional data. The FDA did not ask the company to conduct new clinical trials.

The FDA is set to decide on the newly accepted application by May 21, 2020.

APL-130277 was originally developed by Cynapsus Therapeutics Inc., which was acquired by Sunovion in October 2016.

Sunovion is an indirect, wholly owned subsidiary of Japanese pharmaceutical company Sumitomo Dainippon Pharma Co. Ltd.